US20090069233A1

US20090069233A1 - Agonist Peptides of Basic Fibroblast Growth Factor (bFGF) and the Method of Reduction of Wrinkles on Skin, Darkening of Hair and Acceleration of Wound Healing

Info

Publication number: US20090069233A1
Application number: US12/066,786
Authority: US
Inventors: Abburi Ramaiah
Original assignee: Individual
Current assignee: Individual
Priority date: 2005-09-13
Filing date: 2006-09-11
Publication date: 2009-03-12
Also published as: US8314065B2; AU2006290251B2; US20100323962A1; EP1942923A4; EP2489363A3; EP1942923A1; AU2006290251A1; AU2006290251A2; EP2489363A2; WO2007032029A1

Abstract

The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8.

Description

FIELD OF INVENTION

This invention relates to agonist peptides of basic fibroblast growth factor (bFGF) and the method of reduction of wrinkles on skin, darkening of hair and acceleration of wound healing.

BACKGROUND OF THE INVENTION

Basic fibroblast growth factor (bFGF) also known as FGF2 no named because it contains a high number of basic amino acid residues (Lysin, Arginie and histidine) is a potent mitogen for a variety of cell types including melanocytes, keratinocytes the major cell type in the epidermal unit and fibroblasts located in the dermis of skin. Both bovine and human bFGF were isolated and the genes expressing this product were sequenced and cloned. In addition bFGF was found to be expressed in a wide variety of tissue types including placenta, keratinocytes, fibroblasts.
We have earlier described that bFGF may be involved in repigmentation of vitiligo macules a pigmentary disorder characterized by patchy depigmentation of skin (Ramaiah A, Puri, N, and Majamdar. M A new hypothesis for etiology of vitiligo in Acta Derma Venereol (Stochhom), 1989, 69, 323-327). This idea was tested first on the vitro melanocyte cell cultures from the uninvolved areas of untreated vitiligo subjects and later on mixed cell cultures of melanocytes and keratinoytes obtained from the uninvolved areas of untreated vitiligo subjects. The results demonstrated that bFGF corrects all the abnormalities of melanocytes obtained from the uninvolved areas of untreated vitiligo subjects. An animal model was developed to resemble vitiligo to test the efficacy of interdermal injection bFGF on the rate of repigmentation of depigmented ear lobes of Guinea pigs and depigmented ears lobes of Guinea pigs and depigmented skin patches of Yucatan swine. They were found effect. Peptides ranging from deca peptide to 24 amino acid long peptide were tested for their efficacy to repigment the depigmented ear lobes of Guinea pigs and the depigmented skin patches of Yucatan swine. These peptides were shown to be specific since other growth factors like epidermal growth factor or peptide 1-12 of bFGF did not have any effect on the repigmenting depigmented patches on the experimental animals.
Patents of interest describing bFGF or peptides described above and the formulation for their penetration through intact skin include U.S. Pat. No. 6,143,723, AU Patent 722626, Indian Patents, 185613, 186437, 185703.
The peptides were tested on human volunteers suffering from vitiligo in the various phase of clinical trials in India and found to be successful in repigmenting about more than 80% volunteers with stable generalized vitiligo and segmental vitiligo.
Skin is subject to aging and is visible to the naked eyes. The aging process of skin can be divided into chrono aging and photo aging. The former is a normal aging process and can be accelerated by the exposure of skin to sun, which is known as photo aging. In addition, skin is subject to deterioration through the dermatological disorders, environmental abuse.
Exposure of white/very fair skin to ultraviolet radiation results in more wrinkling of skin than the more pigmented skin. Wrinkles of skin are a reminder to the individual that he/she is looking older and therefore likes to reduce the skin wrinkles by application to skin various cosmetic creams/moisturizers or failing that to various forms of cosmetic surgery which treat or delay the visible signs of chrono aging/photo aging such as wrinkles, liens, sagging etc.
There is bulk of epidemiological literature relating thinning of skin to aging. Collagen-1 represents more than 70% (Uitto J. Connective tissue biochemistry of the aging dermis: Age related alterations in collagen and elastin: Dermatio. Clin (1986) 4:433-46) of the dermis of the skin. Dermal collagen content peaks in the third decade of life and declines gradually at a rate approximately 1% per year thereafter in men and women (Artho P. Skin thickness and collagen content in some endocrine, connective tissue and skin diseases. Acta derm. Veneroeol Suppl (Stockh) 1972: 69:1-48. Meema H E, Sheppard R H, Roentgeno graphic visualization and measurement of skin thickness and its diagnostic application to acromegaly, Radiology (1964); 82:411-7, Shuster S, Black M M, Mc Vitie E. The influence of age and sex on skin thickness, skin collagen and density Br J Dermatol (1975); 93:639-43, Shuster S Bottoms E senile feneration of skin collagen in men. In women it may be so after the fifth decade of life.
Collagen is the predominant matrix skin protein and is known to impart tensile strength to skin. Decorin is proteoglycan, which is known to be important for controlled and correct deposition of collagen in the extracellular matrix of skin. It is also known in the art that the levels of collagen and decorin in skin are significantly reduced with age and/or photo damaged skin. Many studies had shown that the levels of collagen type 1 in skin are decreased with age and/or with increased photo damage (Lavaker R, Jour. Invest. Dermatol (1979); 73:59-66 Griffiths et al New. Eng J. med (1993); 329, 530-535). In the case of decorin, it has been shown that Mrna expression of the proteoglycan is greatly reduced in photo-damaged skin in vitro (Bernstein et al Lal. Invest (1995); 72:662-669). The reduction of the levels of these skin proteins is accordingly associated with collagen, elastin also is lost with age. So the skin gets thinner with age and has tougher time getting enough moisture to the epidermis. At about the same tie the fat in the subcutaneous layer (which gives skin a plump firm appearance) also begins to disappear. The epidermis begins to sag, and wrinkles form. Wrinkles are then prone in the face where facial muscle contractions have been repeated for over many years.
In addition to gradually ageing and sun exposure there are a number of other factors that can contribute increased wrinkles. Some of these can be controlled while others can not. The most common factors that determine wrinkle occurrence include the following:

Heredity

Skin type

Smoking

Hair style
Sun exposure

Drug use

Wrinkles on the face are due to repeated nerve stimulation that result in repeated facial muscle contractions, in addition to reduction in the amount of collagen, elastin and subcutaneous fat in the skin. All anti wrinkling agents which reduce the nerve stimulation and thus facial muscle contractions can help in the reduction of fine lines and wrinkles on the face.
Wrinkle reduction on the rest of the skin on the body including the skin on the face should essentially be by increasing the synthetic of collagen, retention in the skin of moisture.
It is well known in the art that retionic acid is potent anti-aging agent and induces dermal repair of photo damaged skin. It was shown that wrinkle effacement and dermal repair following topical treatment of skin with retionic acid arises through new collagen deposition and synthetic in skin (Griffiths et al New, Eng. J, Med (1993); 329, 530-535).

OBJECTS OF THE INVENTION

An object of the present invention is to propose a peptide and composition containing said peptide for reducing the formation of wrinkles on skin.
Another object of this invention is to propose a peptide and a composition containing said peptide, for darkening of hair.

BRIEF DESCRIPTION OF THE INVENTION

According to this invention there is provided the peptides consisting of sequence 1-8 listed herein for darkening and reduce formation of wrinkles on skin. The peptides are present in the range of 0.02-5% w/w in the composition are effective when applied topically in the formulation for reduction of wrinkles on skin, in acceleration of wound healing and in darkening of hair. They can be applied in the form of lotion, gels, creams or in the case of wound healing in the form of sterile phosphate buffer isotonic saline or in glycerine if applied to cure muscositis in oral cavity. The mode of administration is not restricted to the above methods.

EXAMPLE 1

Anti Wrinkle

20 normal volunteers with clear skin were chosen for this clinical trial. The application of either placebo (formulation) on the right dorsal part of the hand or the formulation containing the peptide was topically applied on the left dorsal hand of the volunteer once a day for 6 weeks and the pictures were taken at the end of such trial.
The results indicated that topical application of the peptide in the formulation once a day for 6 weeks resulted without exception in reduction in wrinkles. A representative photograph after 6 weeks of application of the peptide in the formulation on dorsal hand reduced wrinkles as compared to the control where only the formulation was topically applied. On stopping of the topical application of the peptide lotion, the skin returns to normal in about 2-2 and half months. This effect is thus not permanent. The reduction of wrinkles on skin by the topical application of the bFGF derived peptide described above may be due to increased cellularity of the epidermis and also increased synthesis of collagen. FIG. 1 shows the hand of a volunteer after application of the composition for 6 weeks, and when applied only for 6 weeks.

EXAMPLE 2

Drawing of Hair

In addition, during the clinical trial of its use for the treatment of vitiligo it was observed that the peptides were able to repigment white hair located in the vitiligo macules. Therefore, these peptides increase the proliferation of melanocytes located not only in the dermal epidermal junction but also the melaonocytes located in the hair follicles, as indicated in the taken before and after the topical application of these peptides for 3-6 months.
Peptides Derived from bFGF Accelerate Wound Healing
Advanced wound care technologies have emerged from the shadow to become, in the last 20 years, significant products in wound treatment. While conventionally made wound care products are considerable and generally less expensive, new products and biotechnological advancements are beginning to revolutionize the wound care market. New technological products are competing in a fast track market that seeks to improve the quality of life for millions of individuals needing both acute and chronic wound care.
The subcutaneous implantation of poly-vinyl alcohol sponges had been used to generate artificial wound space. Healing process was followed with time by a combination of histological and biochemical analyze of new tissue that grows in to the interstices of the sponge material in presence and absence of recombinant basic fibroblast growth factor. The results of these experiments clearly indicated that recombinant basic fibroblast growth factor acts to increase neo vasculatisation the number of fibroblasts and the deposition of collagen in the wound space. Similar results were seen on wounds of diabetic mice. There were no side effects (Bernstein et al Lab. Invest. (14995); 72: 662-669).
According to this invention there is provided a method of accelerating wound healing on skin by topical application of an effective amount of a composition in sterile phosphate buffered isotonic saline solution that comprises 0.02-5% w/w of at least one peptide selected from a group consisting for SEQ ID NO 1-8 reference may be made to U.S. Pat. No. 6,143,723 and FIG. 3.
The sequence listing is given as follows: —

- (2) Information for Sequence ID NO: 1
  - (i) Sequence Characteristics:
    - (A) Length: 10 amino acids
    - (B) Type: amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: Linear
    - (E) Source: Synthetic, non-bacterial source
  - (ii) Molecular Type: Peptide
  - (vi) Sequence Description: Sequence ID NO: 1:

All sequences of the peptides were described starting from the amino terminus of the peptide: The standard 3-letter description of the amino acid was used.

	Tyr Arg Ser Arg Lys Tyr Ser Ser Trp Tyr amide
	1 10

- (2) Informations for sequence ID NO: 2:
  - (i) Sequence Characteristics:
    - (A) Length: 10 amino acids
    - (B) Type: amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: linear
    - (E) Source: Synthetic, Non-bacterial source
  - (ii) Molecular type: Peptide
  - (vi) Sequence Description: Sequence ID NO: 2:
  - an invention Tyr Arg Ser Arg Lys Tyr Glu Ser Trp Tyr amide
- (2) Informations for sequence NO: 3:
  - (i) Sequence characteristics:
    - (A) Length: 10 amino acids
    - (B) Type amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: Cyclic
    - (E) Source: Synthetic, Non Bacterial source
  - (ii) Molecular Type: Peptide
  - (vi) Sequence Description: Sequence ID NO: 3:

Cyclo (Tyr Arg Ser Arg Lys Tyr Glu Ser Trp Tyr)
1 10

- (2) Informations for sequence ID NO: 4:
  - (i) Sequence Characteristics:
    - (A) Length: 11 amino acids
    - (B) Type: amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: cyclic
    - (E) Source: Synthetic, Non-bacterial source
  - (ii) Molecular type: Peptide
  - (vi) Sequence Description Sequence ID NO: 4
  - Cyclo (Gly Tyr Arg Ser Arg Lys Tyr Ser Ser Arg Tyr)
- (2) Informations for sequence ID NO: 5:
  - (i) Sequence Characteristics:
    - (A) Length: 15 amino acids
    - (B) Type amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: Linear
    - (E): Source: Synthetic, Non-bacterial source
  - (ii) Molecular Type: Peptide
  - (vi) Sequence Description: Sequence ID NO: 5:

Tyr Arg Ser Arg Lys Tyr Ser Ser Trp Tyr Val Ala
1 10

Leu Lys Arg
15

- (2) Informations for seq. ID NO: 6:
  - (i) Sequence Characteristics:
    - (A) Length: 24 amino acids
    - (B) Type: amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: Linear
    - (E) Source: Synthetic, Non-bacterial source
  - (ii) Molecular type: Peptide
  - (vi) Sequence Description: seq. ID NO: 6:

Pro Ala Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe

Pro Pro Gly His Phe Lys Asp Pro Lys Arg Leu Tyr
20 24

- - (vi) Sequence description: Sequence ID NO: 7
- (2) Informations for sequence NO: 7
  - (i) Sequence characteristics
    - (A) Length: 10 amino acid residues
    - (B) Type: amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: linear
    - (E) Source: Synthetic, Non bacterial source
  - (ii) Molecular type: Peptide
  - (vi) Sequence description: Sequence ID NO: 7
  - para hydroxy phenyl propionic-amide-Tyr Arg Ser Arg Lys Tyr Ser Ser Trp Tyr amide
- (2) Informations for Sequence NO:8
  - (i) Sequence characteristics
    - (A) Length: 10 amino acids
    - (B) Type: amino acid
    - (C) Strandedness: Not applicable
    - (D) Topology: linear
  - (ii) Molecular type: Peptide
  - (vi) Sequence description ID NO: 8
  - Tyr Arg Ser Arg Lys Tyr Ser Ser Trp Tyr-NH(CH2)2C6H40Hp

It is to be understood that the present invention is susceptible to changes, adaptations by those skilled in art. Such modifications, changes and adaptations are intended to be within the scope of the present invention, which is further set forth under the following claims:

Claims

1-2. (canceled)

3. A composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair comprising:

a peptide selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8, wherein said peptides are agonist peptides of bFGF; and

an acceptable carrier for topical application.

4. The composition as claimed in claim 3, wherein the peptide is present in an amount of 0.02 to 5% w/w.